HERON THERAPEUTICS, INC. /DE/ (HRTX) Earnings
HERON THERAPEUTICS, INC. /DE/'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Aug 10, 2026
From the latest earnings 8-K
Revenue • FY2025
$154.9M
▲ 7.4%YoY
Diluted EPS • FY2025
-$0.12
▼ 33.3%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from HRTX's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $154.9M | -$20.2M | $113.56M | -$0.12 | -$27.91M | -1.6% | +7.4% |
| FY2024 | $144.28M | -$13.58M | $105.64M | -$0.09 | -$24.23M | -8.0% | +13.6% |
| FY2023 | $127.04M | -$110.56M | $61.94M | -$0.80 | -$60.33M | -87.1% | +18.0% |
| FY2022 | $107.67M | -$182.02M | $52.8M | -$1.67 | -$148.74M | -162.2% | +24.7% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Aug 10, 2026 | 8-K (2.02) | 0001193125-26-341300EDGAR |
| May 11, 2026 | 8-K (2.02) | 0001193125-26-215752EDGAR |
| Feb 26, 2026 | 8-K (2.02) | 0001193125-26-073502EDGAR |
| Nov 4, 2025 | 8-K (2.02) | 0001193125-25-263617EDGAR |
| Aug 8, 2025 | 8-K (2.02) | 0000950170-25-105474EDGAR |
| May 6, 2025 | 8-K (2.02) | 0000950170-25-063973EDGAR |
| Feb 27, 2025 | 8-K (2.02) | 0000950170-25-028372EDGAR |
| Nov 12, 2024 | 8-K (2.02) | 0000950170-24-124626EDGAR |
Never miss a HRTX filing.
Get an email when HRTX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 8, 2026Source: SEC EDGAR.